Physician profile
Daniel M Gold
NPI 1811980980
$2,945.57
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $231 · 2021: $433 · 2022: $549 · 2023: $703 · 2024: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,620.47 | 2019-2024 | Clareon, Acrysof, Centurion |
| Abbvie INC. | $299.75 | 2022-2024 | |
| Sight Sciences, INC. | $205.23 | 2021-2023 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $135.16 | 2021-2023 | Dextenza |
| Glaukos Corporation | $123.42 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Oyster Point Pharma, INC. | $99.90 | 2022-2023 | Tyrvaya |
| Omeros Corporation | $97.92 | 2019-2021 | |
| Allergan, INC. | $70.66 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.09 | 2019-2021 | |
| Dompe US, INC. | $48.92 | 2021-2024 | Oxervate |
| Bausch & Lomb Americas INC. | $47.87 | 2022-2023 | Stellaris |
| Shire North American Group INC | $39.01 | 2019 | |
| Biotissue Holdings INC. | $30.98 | 2023-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $19.78 | 2019 | |
| Ivantis, INC | $19.41 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $18.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.